چاپ صفحه |  صفحه نخست سامانه |  چکیده مقاله |  نویسندگان |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| showed that improvements in eff icacy noted at 5 years with the addition of docetaxel to anthracycline-based treatment were maintained at 10 years for both progression-free survivial and overall survival in women with nodepositive breast cancer.2 Congestive heart failure—one of two important late-term toxic eff ects of anthracyclines in the adjuvant treatment of breast cancer—was reported for 26 (3%) of 744 patients given docetaxel, doxorubicin, and cyclophosphamide (TAC), and for 17 (2%) of 736 given fl uorouracil, doxorubicin, and cyclophosphamide (FAC; p=0·175). The second toxic eff ect, secondary haematological malignancies, will be a growing problem in the near future with regards to increased survival. These malignancies arise in 0·3–1·7% of patients with breast cancer who are receiving antineoplastic chemotherapy.3–5 In the 10 year analysis, the BCIRG 001 study investigators reported secondary hematological malignancies in six patients in the TAC group and three patients in the FAC group (p=0·51). The absence of a significant diff erence between the two groups might be related to the low frequency of these events. The heightened risk in patients given TAC might be attributable to the increased use of granulocyte colonystimulating factor (G-CSF) in this group; however, no directly reported data are available. Use of G-CSF was mandatory after the first episode of febrile neutropenia in the study, and febrile neutropenia was more frequent in TAC patients than in those given FAC |
| نویسنده | نفر چندم مقاله |
|---|---|
| صمد اسلام جمال گلزاری | اول |
| کامیار قابیلی | دوم |
| رضا ریخته گر غیاثی | پنجم |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| L-Cancer drug.pdf | 1398/09/13 | 36255 | دانلود |
